MLN8054 – 25 mg

Brand:
Cayman
CAS:
869363-13-3
Storage:
-20
UN-No:
Non-Hazardous - /

MLN8054 is an ATP-competitive inhibitor of Aurora A kinase (IC50 = 4 nM).{53240} It is selective for Aurora A over Aurora B, PKC, CaMKII, Cdk2E, CK2, LCK, PKA, Chk1, Chk2, Cdk1, and Plk1 (IC50s = 0.172-100 µM). MLN8054 induces cell cycle arrest at the G2/M phase and the formation of abnormal mitotic spindles in HCT116 colorectal and PC3 prostate cancer cells. It inhibits the growth of HCT116, SW480, DLD-1, MCF-7, MDA-MB-231, Calu-6, H460, SKOV3, and PC3 cancer cells (IC50s = 0.11-1.43 µM). MLN8054 (30 mg/kg) reduces tumor volume in HCT116 and PC3 mouse xenograft models.  

 

Available on backorder

SKU: 27340 - 25 mg Category:

Description

An inhibitor of Aurora A kinase (IC50 = 4 nM); selective for Aurora A over Aurora B, PKC, CaMKII, Cdk2E, CK2, LCK, PKA, Chk1, Chk2, Cdk1, and Plk1 (IC50s = 0.172-100 µM); induces cell cycle arrest at the G2/M phase and the formation of abnormal mitotic spindles in HCT116 colorectal and PC3 prostate cancer cells; inhibits the growth of various cancer cells (IC50s = 0.11-1.43 µM); reduces tumor volume in HCT116 and PC3 mouse xenograft models at 30 mg/kg


Formal name: 4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-benzoic acid

Synonyms: 

Molecular weight: 476.9

CAS: 869363-13-3

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|Aurora||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Cycle||Research Area|Cancer|Cell Signaling